

## Increased Estimated 10-Year Risk for Cardiovascular Disease Assessed Using the Pooled Cohort Equation in Non-Diabetic Subjects According to Increasing HbA1c Levels

Hyung-Geun Oh<sup>1</sup>, Eun-Jung Rhee<sup>2</sup>

<sup>1</sup>Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea

<sup>2</sup>Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

**Objective:** In 2013, a new risk calculator known as the Pooled Cohort Equation (PCE) was introduced with the new cholesterol guideline. We aimed to calculate the 10-year atherosclerotic cardiovascular disease (ASCVD) risk using PCE in non-diabetic Korean subjects with glycated hemoglobin (HbA1c) lower than 6.5%.

**Methods:** A total of 17,519 participants were evaluated in a health screening program. The 10-year ASCVD risk was calculated using the PCE. Subjects with underlying diabetes or HbA1c  $\geq 6.5\%$  were excluded. Subjects were divided into four groups according to fasting blood glucose (FBG) and HbA1c levels: FBG  $<100$  mg/dL,  $100 \leq \text{FBG} < 110$  mg/dL,  $110 \leq \text{FBG} < 120$  mg/dL, and FBG  $\geq 120$  mg/dL; HbA1c  $< 5.5\%$ ,  $5.5\% \leq \text{HbA1c} < 5.6\%$ ,  $5.6\% \leq \text{HbA1c} < 5.8\%$ , and HbA1c  $\geq 5.8\%$ .

**Results:** The mean 10-year ASCVD risk significantly increased as FBG increased from  $<100$  mg/dL to  $>120$  mg/dL in the four divided groups (2.6%, 3.3%, 3.8%, 4.1%;  $p < 0.01$ ), and as HbA1c increased from  $< 5.5\%$  to  $> 5.8\%$  (2.4%, 2.7%, 3.0%, 3.6%;  $p < 0.01$ ). The odds ratio for 10-year ASCVD risk  $\geq 10\%$  significantly increased from group I to IV according to FBG and HbA1c levels after adjusting for age, body mass index and fasting insulin level (1.187, 1.753, and 2.390 vs. 1.0 in the lowest FBG group; 1.626, 1.574, and 1.645 vs. 1.0 in the lowest HbA1c group).

**Conclusion:** The 10-year ASCVD risk calculated using the PCE significantly increased as the FBG and HbA1c increased even in Korean subjects without underlying diabetes.

**Key Words:** Pooled Cohort Equation, 10-year cardiovascular disease risk, Prediabetes

## INTRODUCTION

Prediabetes is an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.<sup>1</sup> According to the 6<sup>th</sup> Diabetes Atlas, the number of individuals with prediabetes is almost similar to the number of patients with diabetes worldwide.<sup>2</sup> This increasing trend deteriorates as time progresses and the

health economic burden due to this problem is huge. Considering the socioeconomic burden of diabetes and the potential of prediabetes to progress to diabetes, the prevention of this progression is the most important strategy to overcome the global burden of cardiovascular disease associated with diabetes.

It has been reported that atherosclerosis occurs in the prediabetic stage and even progress. The Collaborative

Received: September 18, 2015

Revised: November 20, 2015

Accepted: December 9, 2015

**Corresponding Author:** Eun-Jung Rhee, Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 108 Pyungdong, Jongro-gu, Seoul 110-746, Korea  
Tel: +82-2-2001-2485, Fax: +82-2-2001-1588, Email: hongisiri@hanmail.net

This is an Open Access article distributed under the terms of the creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

analysis Of Diagnostic Criterion in Europe (DECODE) study confirmed that asymptomatic hyperglycemia was associated with an increased risk of premature mortality and cardiovascular disease.<sup>3</sup> In the Diabetes Epidemiology: Collaborative Analysis Of Diagnostic Criterion in Asia (DECODA) study, the correlation between glycemic status in the non-diabetic range and mortality due to CVD was also confirmed among Asians.<sup>4</sup> These two studies showed that post-challenge hyperglycemia other than fasting hyperglycemia had a higher correlation with CVD risk.

The Framingham Risk Score (FRS), which has been derived from the data from Caucasians, has been used for the calculation of the 10-year CVD risk with the view to identify subjects who are eligible for statin treatment according to the cholesterol guideline.<sup>5</sup> However, there are still controversies regarding the appropriateness of applying this risk calculator to other ethnic groups. In 2013, the American College of Cardiology/American Heart Association (ACC/AHA) task force released a new report on the treatment of blood cholesterol.<sup>6</sup> This guideline included a new risk assessment tool designated Pooled Cohort Equations (PCE) to quantify the 10-year atherosclerotic CVD (ASCVD) risk, which has been the subject of controversy regarding its accuracy in risk prediction.<sup>7</sup> In this respect, only a few studies have reported the predictive power of the PCE using other datasets.

To date, no studies have evaluated the 10-year ASCVD risk in subjects with prediabetes using PCEs. Therefore, herein we analyzed the 10-year ASCVD risk using the PCE in 17,519 Korean subjects who participated in a health screening program, and compared these rates across different groups stratified by fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels.

## MATERIALS AND METHODS

### 1. Study subjects

This cross-sectional study was part of the Kangbuk

Samsung Health Study (KSHS), in which the subjects were evaluated in a medical health checkup program at the Health Promotion Center of Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea. The purpose of this checkup program was to promote the health of employees through regular health checkups and to enhance early detection of existing diseases. Most of the examinees are employees and family members of various industrial companies from around the country. The costs of the medical examinations are largely paid for by their employers and a considerable proportion of the examinees undergo examinations annually or biannually.

The initial study population comprised 34,464 subjects who participated in the program between January 2011 and December 2012. Among them, 20,937 subjects aged between 40 and 75 years were selected. In addition, the subjects with diabetes, being treated with hyperlipidemic agent and those with missing data were excluded from the study, leaving 17,519 subjects for the final analysis.

The study was approved by the institutional review board of Kangbuk Samsung Hospital. The requirement of informed consent was waived because we used non-identifiable data routinely collected during the health screening process.

### 2. Anthropometric measurement and laboratory assessment

Height and weight were measured twice and then averaged. Body mass index (BMI) was calculated by dividing the weight (kg) by the square of the height (m). Blood pressure was measured using a standardized sphygmomanometer after 5 minutes of rest.

All of the subjects were examined after an overnight fast. The hexokinase method was used to measure fasting blood glucose (FBG) concentrations (Hitachi Modular D2400; Roche, Tokyo, Japan). An enzymatic calorimetric test was used to measure the total cholesterol and triglyceride concentrations. The selective inhibition method

was used to measure the level of high-density lipoprotein cholesterol (HDL-C), and a homogeneous enzymatic calorimetric test was used to measure the level of low-density lipoprotein cholesterol (LDL-C).

HbA1c was measured using an immunoturbidimetric assay with a Cobra Integra 800 automatic analyzer (Roche Diagnostics, Basel, Switzerland) with a reference value of 4.4%-6.4%. The methodology was aligned with the Diabetes Control and Complications Trial and National Glycohemoglobin Standardization Program (NGSP) standards.<sup>8</sup> The intra-assay coefficient of variation (CV) was 2.3% and the inter-assay CV was 2.4%, both of which were within the acceptable limits of the NGSP.<sup>9</sup>

The presence of diabetes mellitus was determined using a self-reported questionnaire applied to the participants and according with the diagnostic Criterion of the American Diabetes Association (ADA).<sup>1</sup> Whether the subject was on anti-hypertensive medication or not was assessed using the self-reported questionnaire. The smoking status was also determined using the questionnaire and current smokers were defined as the subjects who responded yes to the question "Do you currently smoke?" in the questionnaire. Alcohol drinking status was assessed by the self-questionnaire, and confirmed 'yes' if the subject was drinking alcohol equal to or more than three times a weeks.

Subjects were divided into four groups according to the FBG levels, as follows: group I: FBG<100 mg/dL, group II: 100≤FBG<110 mg/dL, group III: 110≤FBG<120 mg/dL, and group IV: FBG≥120 mg/dL.

In addition, subjects were divided into four groups according to the HbA1c quartile, as follows: 1<sup>st</sup> quartile: HbA1c<5.5%, 2<sup>nd</sup> quartile: 5.5%≤HbA1c<5.6%, 3<sup>rd</sup> quartile: 5.6%≤HbA1c<5.8%, and 4<sup>th</sup> quartile: HbA1c≥5.8%.

### 3. Assessment of the 10-year cardiovascular disease risk using the Pooled Cohort Equation

The 10-year ASCVD risk was assessed using the PCE

as recommended by the 2013 ACC/AHA guideline on the treatment of blood cholesterol.<sup>7</sup> The PCE assesses the 10-year ASCVD risk considering data on age, ethnic group (African-American vs. Caucasians or others), gender, total cholesterol, HDL-C, systolic blood pressure, treatment with anti-hypertensive medications, smoking status, and the presence of diabetes. The proportion of subjects with 10-year ASCVD risk were assessed and the risk for being 10-year ASCVD≥7.5% were analyzed.

### 4. Statistical analysis

All data were presented as the mean and standard deviation and were analyzed using PASW Statistics software version 18.0 (SPSS Inc., Chicago, IL, USA). The comparisons of the mean values and the prevalence of the variables among the four groups divided by HbA1c and FBG were performed with one-way analysis of variance (ANOVA) test and chi-square test. Multiple comparisons of differences in the means of continuous variables between individual groups were performed using the post-hoc analyses after one-way ANOVA test with Tukey's b test.

Logistic regression analysis was performed to analyze the odds ratio (OR) for increased 10-year ASCVD risk in the four groups divided by HbA1c and FBG. Statistical significance was defined by a *p* value less than 0.05.

## RESULTS

The general characteristics of the participants are presented in Table 1. The mean age of the participants was 46 years and 79.3% were men. The mean BMI was 24.3 kg/m<sup>2</sup> and the mean HbA1c was 5.66%.

The classification of the groups according to the FBG levels indicated that the subjects in the highest group were the oldest and the most obese among the four groups (Table 3). The mean 10-year ASCVD risk increased as the mean FBG increased from the lowest to the highest group,

although groups III and IV did not show any significant differences in the post-hoc analyses (Table 2).

The classification of the groups according to HbA1c

Table 1. General characteristics of the participants

N=17,519	Variables
Age (years)	45.8±5.8
Gender: men (%)	13,899(79.3)
BMI (kg/m <sup>2</sup> )	24.3±2.9
Systolic BP (mmHg)	113.8±12.6
Diastolic BP (mmHg)	74.5±10.1
Fasting blood glucose (mg/dL)	97.2±8.8
Total cholesterol (mg/dL)	205.6±32.6
HDL-C (mg/dL)	54.0±13.2
Triglyceride (mg/dL)	136.4±81.0
LDL-C (mg/dL)	132.2±30.0
HbA1c (%)	5.66±0.3
Current smoking (%)	4,794(27.4)
Alcohol drinking (%)	3454(19.7)
Treatment for hypertension (%)	830(4.7)
Mean 10-year cardiovascular risk	2.91±2.9

BMI; body mass index, BP; blood pressure, HDL-C; high-density lipoprotein cholesterol, HbA1c; glycated hemoglobin

quartiles indicated that the subjects in the 4<sup>th</sup> quartile were the oldest and mostly obese among the four groups (Table 2). Other metabolic parameters showed a significant increase from the lowest to the highest quartile groups. The mean 10-year ASCVD risk increased as the mean HbA1c increased from the lowest to the highest quartile group (Table 3).

When logistic regression analyses were performed with the 10-year cardiovascular risk of  $\geq 7.5\%$  as the dependent variable, the OR increased from group I to IV according to the FBG (Table 4). This significance was maintained even after adjusting for age, BMI, and fasting insulin levels. When 10-year ASCVD risk of  $\geq 7.5\%$  was calculated according to 10 mg/dL of FBG increment, OR was 1.208 after adjustment for age, BMI, and fasting insulin levels (Table 4).

When the OR for the 10-year ASCVD risk of  $\geq 7.5\%$  was analyzed using logistic regression according to the

Table 2. Comparisons of the parameters in 4 groups according to the fasting blood glucose levels

N=17,519	Group I (N=11279)	Group II (N=4624)	Group III (N=1333)	Group IV (N=283)	p value
Age (years)	45.6±5.7	46.1±5.9	46.6±6.0 <sup>†</sup>	46.8±5.6 <sup>†</sup>	<0.01
Gender: men (%)	8453(74.9)	3991(86.3)	1193(89.5)	262(92.6)	<0.01
BMI (kg/m <sup>2</sup> )	23.9±2.8	24.8±2.8	25.4±3.0	25.8±2.7	<0.01*
Systolic BP (mmHg)	111.9±12.2	116.0±12.3	119.6±13.4	121.6±13.5	<0.01*
Diastolic BP (mmHg)	73.0±9.7	76.4±10.0	78.9±10.6	80.3±10.5	<0.01*
Fasting blood glucose (mg/dL)	92.0±5.1	103.7±2.8	113.4±2.7	122.3±2.0	<0.01*
Total cholesterol (mg/dL)	203.6±32.3	208.3±32.5	211.8±33.8 <sup>†</sup>	212.5±34.2 <sup>†</sup>	<0.01
HDL-C (mg/dL)	54.8±13.4	52.9±12.8	51.5±12.2 <sup>†</sup>	51.2±12.2 <sup>†</sup>	<0.01
Triglyceride (mg/dL)	126.6±74.5	148.3±84.5	167.1±99.6	183.1±94.9	<0.01*
LDL-C (mg/dL)	130.7±29.9	134.4±30.0 <sup>†</sup>	136.6±30.1 <sup>†</sup>	135.8±31.4 <sup>†,†</sup>	<0.01
HbA1c (%)	5.61±0.2	5.72±0.2	5.85±0.3	5.98±0.3	<0.01*
Current smoking (%)	2991(26.5)	1319(28.5)	391(29.3)	93(32.9)	0.003
Alcohol drinking (%)	1875(16.6)	1107(23.9)	373(28.0)	99(35.0)	<0.01
Treatment for hypertension (%)	415(3.7)	269(5.8)	109(8.2)	37(13.1)	<0.01
Mean 10-year CVD risk	2.62±2.7	3.26±3.0	3.83±3.2 <sup>†</sup>	4.12±3.1 <sup>†</sup>	<0.01
Proportion of subjects with 10-year CVD risk $\geq 7.5\%$	666(5.9)	392(8.5)	164(12.3)	398(13.8)	<0.01

BP; blood pressure, HDL-C; high-density lipoprotein cholesterol, HbA1c; glycated hemoglobin, CVD; cardiovascular disease  
Group I: FBG <100 mg/dL, group II: 100≤FBG<110 mg/dL, group III: 110≤FBG<120 mg/dL, group IV: FBG≥120 mg/dL

\*Significant differences among the different groups in post-hoc analyses

<sup>†,†</sup>Different footnotes denote significant differences between the groups in post-hoc analyses. Same footnote denotes lack of significant differences between the groups in post-hoc analyses. Otherwise significant difference in post-hoc analysis. Values are presented as mean±standard deviation or number (%).

HbA1c quartile groups, the OR significantly increased from quartile I to IV (Table 4). This significance was maintained even after adjusting for age, BMI, and fasting insulin level. When 10-year ASCVD risk of  $\geq 7.5\%$  was calculated according to 1% of HbA1c increment, OR was 1.367 after

adjustment for age, BMI, and fasting insulin levels (Table 4).

## DISCUSSION

In this study, we observed that the estimated 10-year

Table 3. Comparisons of the parameters according to HbA1c quartiles

N=17,519	1 <sup>st</sup> quartile (N=3549)	2 <sup>nd</sup> quartile (N=5282)	3 <sup>rd</sup> quartile (N=4847)	4 <sup>th</sup> quartile (N=3841)	p value
Age (years)	44.9±4.8	45.3±5.2	46.1±5.9	47.2±6.8	<0.01*
Gender: men (%)	2872(80.9)	4282(81.1)	3825(78.9)	2920(76.0)	<0.01
BMI (kg/m <sup>2</sup> )	23.8±2.7	24.0±2.8	24.4±2.8	25.0±3.0	<0.01*
Systolic BP (mmHg)	113.2±12.6a	113.3±12.4a	113.9±12.7	114.7±12.9	<0.01
Diastolic BP (mmHg)	74.1±10.3a	74.2±10.1a	74.6±9.9	75.1±10.1	<0.01
Fasting blood glucose (mg/dL)	93.8±7.6	95.7±7.9	97.5±8.2	102.1±9.7	<0.01*
Total cholesterol (mg/dL)	198.2±30.9	203.9±31.8	208.5±32.4	211.0±34.0	<0.01*
HDL-C (mg/dL)	55.5±13.4	54.9±13.4	53.6±12.9	51.9±12.7	<0.01*
Triglyceride (mg/dL)	125.3±73.8	130.4±78.0	140.2±83.2	150.0±86.3	<0.01*
LDL-C (mg/dL)	125.3±28.6	130.6±29.5	134.7±29.8	137.6±31.0	<0.01*
HbA1c (%)	5.31±0.1	5.55±0.04	5.74±0.05	6.02±0.14	<0.01*
Current smoking (%)	953(26.9)	1515(28.7)	1303(26.9)	1023(26.6)	0.083
Alcohol drinking (%)	802(22.6)	1087(20.6)	882(18.2)	683(17.8)	<0.01
Treatment for hypertension (%)	140(3.9)	203(3.8)	227(4.7)	260(6.8)	<0.01
Mean 10-year CVD risk	2.39±2.4	2.69±2.7	3.01±2.9	3.55±3.4	<0.01*
Proportion of subjects with 10-year CVD risk $\geq 7.5\%$	148(4.2)	299(5.7)	373(7.7)	441(11.5)	<0.01

BP; blood pressure, HDL-C; high-density lipoprotein cholesterol, LDL-C; low-density lipoprotein cholesterol, HbA1c; glycated hemoglobin CVD, cardiovascular disease

1<sup>st</sup> quartile: HbA1c<5.5, 2<sup>nd</sup> quartile: 5.5≤HbA1c<5.6, 3<sup>rd</sup> quartile: 5.6≤HbA1c<5.8, 4<sup>th</sup> quartile: HbA1c≥5.8%

\*Significant differences between the different groups in post-hoc analyses

†Same footnotes denote lack of significant differences between the groups in post-hoc analyses

Table 4. Odds ratio for the increased 10-year cardiovascular risk according to different groups classified according to HbA1c and fasting glucose levels

Groups by FBG*	Crude OR for 10-year CVD risk $\geq 7.5\%$	OR for 10-year CVD risk $\geq 7.5\%$ †
Group I	1.00	1.00
Group II	1.476(1.296, 1.681)	1.197(1.030, 1.390)
Group III	2.236(1.865, 2.680)	1.592(1.288, 1.967)
Group IV	2.547(1.800, 3.603)	1.624(1.091, 2.417)
Increment by 10 mg/dL	1.407(1.322, 1.497)	1.208(1.123, 1.300)
HbA1c quartiles**	Crude OR for 10-year CVD risk $\geq 7.5\%$	OR for 10-year CVD risk $\geq 7.5\%$ †
1 <sup>st</sup> quartile	1.00	1.00
2 <sup>nd</sup> quartile	1.379(1.127, 1.687)	1.237(0.993, 1.541)
3 <sup>rd</sup> quartile	1.916(1.576, 2.330)	1.276(1.028, 1.583)
4 <sup>th</sup> quartile	2.981(2.460, 3.612)	1.388(1.118, 1.724)
Increment by 1%	4.374(3.516, 5.441)	1.367(1.064, 1.756)

\*Group I: FBG<100 mg/dL, group II: 100≤FBG<110 mg/dL, group III: 110≤FBG<120 mg/dL, group IV: FBG≥120 mg/dL

\*\*1<sup>st</sup> quartile: HbA1c<5.5, 2<sup>nd</sup> quartile: 5.5≤HbA1c<5.6, 3<sup>rd</sup> quartile: 5.6≤HbA1c<5.8, 4<sup>th</sup> quartile: HbA1c≥5.8%

†Adjusted for age, BMI, and fasting insulin level

ASCVD risk calculated using the PCE increased as the FBG increased within the non-diabetic range in apparently healthy Korean adults, although no significant differences were observed between the subjects with  $110 \leq \text{FBG} < 120$  mg/dL and those with  $\text{FBG} \geq 120$  mg/dL. With regard to the HbA1c quartiles, a significantly increased estimated 10-year ASCVD risk was observed as HbA1c increased from 1<sup>st</sup> to 4<sup>th</sup> quartile groups. When logistic regression analysis was performed using the increased 10-year ASCVD risk defined by  $\geq 7.5\%$ , the group with  $\text{FBG} \geq 120$  mg/dL showed a 1.62-fold increased risk for a  $\geq 7.5\%$  10-year ASCVD risk compared with those with  $\text{FBG} < 100$  mg/dL. With regard to HbA1c, the subjects with  $\text{HbA1c} \geq 5.8\%$  showed a 1.34-fold increased risk for a  $\geq 7.5\%$  10-year ASCVD risk compared with those with  $\text{HbA1c} < 5.5\%$ . These results suggest that even within the non-diabetic range, the increase in FBG or HbA1c can increase the cardiovascular risk as calculated using the PCE.

The increased cardiovascular risk in subjects with elevated glucose levels in the non-diabetic range is still a subject of debate. In a large European multicenter study, the DECODE study confirmed that symptomatic hyperglycemia is associated with a higher future risk of mortality due to CVD among individuals with impaired glucose tolerance (IGT) compared with those with impaired fasting glucose (IFG).<sup>3</sup> In contrast, the AusDiab study found that, compared with normal glucose tolerance, the relative risk of developing CVD events was higher among those with IFG compared with those with IGT.<sup>10</sup> Moreover, the Atherosclerosis Risk in Communities (ARIC) study did not find any association between high FBG and coronary heart disease (CHD) or ischemic stroke, whereas HbA1c concentrations of 5.5%-6.0% were associated with a 45% increased risk of CHD but not with ischemic stroke, and HbA1c concentrations of 6.0%-6.5% were associated with a 40%-60% increased risk of both CHD and stroke compared with individuals with HbA1c levels of 5.0%-5.5%.<sup>11</sup> A meta-analysis of 9 prospective studies con-

cluded that a 1%-point increase in HbA1c within the nondiabetic range was associated with a 20% increased risk of CHD.<sup>12</sup>

In 2013, the ACC/AHA task force released a new report on the treatment of blood cholesterol, suggesting the four groups to benefit from statin treatment and removing the specific target levels for blood cholesterol for the reduction of CVD.<sup>6</sup> This guideline recommended the use of a totally new risk assessment tool designated PCEs to assess the 10-year ASCVD risk. PCEs use age, gender, race, total cholesterol, HDL-C, systolic blood pressure, treatment for high hypertension, diabetes, and smoking as risk factors and is different from the Framingham Risk Score (FRS), which uses age, gender, total cholesterol, HDL-C, blood pressure, and smoking as risk factors.<sup>7,12</sup> Although the FRS has been validated in many populations, its accuracy is somewhat limited among Asian populations.

No previous studies have estimated the 10-year ASCVD risk using the PCE for the non-diabetic status. In our study, the estimated 10-year ASCVD risk calculated with the PCE linearly increased as the groups were classified according to FBG and HbA1c. In addition, the subjects with FBG higher than 110 mg/dL showed a significantly increased ( $\geq 10\%$ ) ASCVD risk compared with those with FBG lower than 110 mg/dL. This result suggests that even within the non-diabetic glycemic range, there can be different risk stratification with different glucose levels, particularly among those with FBG higher than 110 mg/dL. This result opposes the rationale of ADA for lowering the normal range of FBG level from 110 mg/dL to 100 mg/dL, which differed from the cutoff of the World Health Organization.<sup>13,14</sup> However, our results support those of previous studies in that subjects with IFG could have increased CVD risk, despite the absence of diabetes in those patients in that instance.<sup>15</sup>

In this study, an increase in HbA1c higher than 5.5% resulted in a linearly increased risk for a 10-year ASCVD risk  $\geq 7.5\%$  calculated with the PCE. The cutoff of 5.5%



was a value defined accidentally when dividing the population into four groups, not an artificial selection. In the ARIC study, subjects with an HbA1c level higher than 5.5% showed a significantly increased risk for CHD.<sup>11</sup> The agreement of the cutoff with that of a previous study in which the ASCVD risk was assessed using the actual occurrence of CVD events could have occurred by chance or it's the actual fact; thus we should interpret the result cautiously.

This study has a few limitations worth noting. First, the glycemic status was assessed only using HbA1c and FBG, and not using a glucose challenge test. Therefore, there could be alterations in the diagnosis of the glycemic status if both FBG and post-challenge glucose had been measured. However, many studies have reported the accuracy of measuring only FBG levels for the detection of diabetes or prediabetes in mass screening programs.<sup>16,17</sup> Secondly, the status of the cardiovascular burden was assessed only using the PCE, not using the actual CVD events. However, the purpose of this study was not to assess the correlations with the real CVD risk, but to observe that the PCE could be validated in subjects with prediabetes. In addition, we aimed to compare the agreement of PCE values with the glycemic status assessed using HbA1c or FBG. Therefore, further studies should be performed to prove the accuracy of the PCE to predict actual CVD events in subjects with prediabetes. In spite of these limitations, this is the first study to analyze the 10-year ASCVD risk calculated using the PCE in subjects with prediabetes.

In conclusion, we found that the 10-year ASCVD risk calculated using the new risk calculator, the PCE, increased linearly as the glycemic status assessed using both HbA1c and FBG worsened in the non-diabetic range in Korean subjects without underlying diabetes. This result corroborates previous findings in which the CVD risk assessed using the PCE increased as the glucose level increased even in the non-diabetic range. Further studies are

necessary to confirm the results of our study in different ethnic groups.

## REFERENCES

1. Standards of medical care in diabetes--2015: summary of revisions. *Diabetes Care* 2015;38 Suppl:S4.
2. International Diabetes Federation. IDF diabetes atlas. 6th ed [Internet]. Brussels: International Diabetes Federation; 2013 [cited 2015 Apr 6]. Available from: [http://www.idf.org/sites/default/files/EN\\_6E\\_Atlas\\_Full\\_0.pdf](http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf).
3. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe*. *Lancet* 1999; 354:617-621.
4. Nakagami T; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. *Diabetologia* 2004; 47:385-394.
5. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008;117:743-753.
6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:S1-S45.
7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63:2935-2959.
8. National Glycohemoglobin Standardization Program. List of NGSP certified methods [Internet]. [place unknown]: National Glycohemoglobin Standardization Program; [cited 2015 Nov 16]. Available from: <http://www.ngsp.org/docs/methods.pdf>.

9. Schwartz KL, Monsur JC, Bartoces MG, West PA, Neale AV. Correlation of same-visit HbA1c test with laboratory-based measurements: a MetroNet study. *BMC Fam Pract* 2005;6:28.
10. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. *Diabetologia* 2009;52:415-424.
11. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med* 2010;362:800-811.
12. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837-1847.
13. Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. *Diabetologia* 2004;47:1396-1402.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-553.
15. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. *J Am Coll Cardiol* 2010;55:1310-1317.
16. Bur A, Herkner H, Woisetschläger C, Vlcek M, Derhaschnig U, Hirschl MM. Is fasting blood glucose a reliable parameter for screening for diabetes in hypertension? *Am J Hypertens* 2003;16:297-301.
17. Ghazanfari Z, Haghdoost AA, Alizadeh SM, Atapour J, Zolala F. A comparison of HbA1c and fasting blood sugar tests in general population. *Int J Prev Med* 2010;1:187-194.